Outcomes by date and period of enrollment before and after suspension
| . | Before regimen A suspension . | Before regimen B suspension . | After regimen C suspension . | A vs C (P) . | B vs C (P) . | Trend (P) . |
|---|---|---|---|---|---|---|
| Date | September 1996 through March 1998 | March 1998 through October 1999 | May 2000 through December 2002 | — | — | — |
| Patients (N) | 205 | 290 | 406 | — | — | — |
| From study entry | ||||||
| OS ± 2 SE | 43 ± 7 (1.60) | 52 ± 6 (1.19) | 57 ± 6 (1.00) | <.001 | .14 | <.001 |
| EFS ± 2 SE | 34 ± 7 (1.42) | 42 ± 6 (1.13) | 46 ± 6 (1.00) | .002 | .250 | .002 |
| TRM ± 2 SE | 19 ± 5 (1.63) | 17 ± 4 (1.43) | 12 ± 3 (1.00) | .025 | .073 | .021 |
| After remission | ||||||
| OS ± 2 SE | 49 ± 8 (1.60) | 57 ± 6 (1.22) | 63 ± 6 (1.00) | .001 | .137 | .001 |
| DFS ± 2 SE | 40 ± 8 (1.42) | 46 ± 6 (1.19) | 51 ± 6 (1.00) | .006 | .138 | .006 |
| . | Before regimen A suspension . | Before regimen B suspension . | After regimen C suspension . | A vs C (P) . | B vs C (P) . | Trend (P) . |
|---|---|---|---|---|---|---|
| Date | September 1996 through March 1998 | March 1998 through October 1999 | May 2000 through December 2002 | — | — | — |
| Patients (N) | 205 | 290 | 406 | — | — | — |
| From study entry | ||||||
| OS ± 2 SE | 43 ± 7 (1.60) | 52 ± 6 (1.19) | 57 ± 6 (1.00) | <.001 | .14 | <.001 |
| EFS ± 2 SE | 34 ± 7 (1.42) | 42 ± 6 (1.13) | 46 ± 6 (1.00) | .002 | .250 | .002 |
| TRM ± 2 SE | 19 ± 5 (1.63) | 17 ± 4 (1.43) | 12 ± 3 (1.00) | .025 | .073 | .021 |
| After remission | ||||||
| OS ± 2 SE | 49 ± 8 (1.60) | 57 ± 6 (1.22) | 63 ± 6 (1.00) | .001 | .137 | .001 |
| DFS ± 2 SE | 40 ± 8 (1.42) | 46 ± 6 (1.19) | 51 ± 6 (1.00) | .006 | .138 | .006 |
Values are percentages ± standard error. Hazard ratio (HR) from multivariate regression is included in parentheses. Estimates are 5 years from study entry and 5 years after induction.
OS indicates overall survival; EFS, event-free survival; TRM, treatment-related mortality; DFS, disease-free survival; and —, not applicable.